OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
This is a summary aggregated from Decrypt. Read the complete article on the original site:
Read full article at Decrypt
